Occult choroidal neovascularization in age-related macular degeneration - A natural history study
Occult choroidal neovascularization in age-related macular degeneration - A natural history study
复制标题
DOI：
10.1001/archopht.1997.01100150347006
复制
发表时间：
1997-03-01
影响因子：
--
通讯作者：
Schachat, AP
中科院分区：
文献类型：
--
作者：
Stevens, TS;Bressler, NM;Schachat, AP
目的：探讨边界不清的中心凹下脉络膜新生血管（CNV）未治疗眼的形态学和视力变化。设计：分析参与前瞻性临床试验的边界不清的隐匿性CNV未治疗患者的照片，评价激光治疗与观察的比较。设置：两个三级视网膜转诊中心。患者：与年龄相关性黄斑变性相关的中心凹下隐匿性CNV分界不清的症状个体。主要结果测量：病变大小的变化，经典CNV的发展，视力的变化和视网膜下纤维化的发展。结果：在随访期间（9-12个月），32%的隐匿性脉络膜新生血管病变的大小增加了一倍以上。52%的无典型CNV的眼睛发生了典型CNV，视力损失的中位数为2.5行。眼睛与经典的CNV或视网膜下血液或两者在基线发展视网膜下纤维化更频繁，失去了更多的视力，但没有统计学意义的degree.Conclusions：的形态变化的眼睛与中央凹下隐匿性CNV的边界划分不清是可变的，视网膜下血液或经典CNV的一个组成部分的存在可能会影响预后进一步丧失视力。
Objective: To explore morphological and vision changes in untreated eyes with subfoveal choroidal neovascularization (CNV) that have poorly demarcated boundaries.Design: Analysis of photographs of untreated patients with poorly demarcated occult CNV participating in a prospective clinical trial evaluating laser treatment compared with observation.Setting: Two tertiary retinal referral centers.Patients: Symptomatic individuals with poorly demarcated subfoveal occult CNV associated with age-related macular degeneration.Main Outcome Measures: Change in size of lesion, development of classic CNV, change in vision, and development of subretinal fibrosis.Results: During follow-up (9-12 months), 32% of the occult choroidal neovascular lesions more than doubled their original size. Classic CNV developed in 52% of eyes that started without it. The median loss in visual acuity was 2.5 lines. Eyes with classic CNV or subretinal blood or both at baseline developed subretinal fibrosis more frequently and lost more visual acuity, but not to a statistically significant degree.Conclusions: The morphological changes of eyes with subfoveal occult CNV in which the boundaries are poorly demarcated is variable; the presence of subretinal blood or a component of classic CNV may influence the prognosis for further loss of vision.